Common Drug Substrates for Cytochrome P450 CYP2C19
Anti-epileptics: VALIUM®
EPANUTIN® NEXIUM®
PPIs: ZOTON® LOSEC®
(diazepam) (phenytoin) (esomeprazole)
(lansoprazole) (esomeprazole)
PANTOZOL® (pantoprazole)
Others: TRYPTIZOL® SANOMA® CELEXA®
7%
(amitriptyline) (carisoprodol)
ANAFRANIL® PLAVIX®
TOFRANIL® TRANDATE® PALUDRINE®
VFEND®
(citalopram) (clopidogrel)
(clomipramine) (imipramine)
(labetalol) (proguanil)
(voriconazole) CYP2B6
WELLBUTRIN® STOCRIN® IFEX®
KETALAR®
MEPHENON® SYMORON®
(bupropion) (ifosfamide)
(efavirenz) (ketamine)
, DENOLIN® (methadone)
,
VIRAMUNE® DIPRIVAN® ELDEPRYL®
(nevirapine)
(propofol) (selegiline)
7%
% of drugs metabolized by
CYP450 CYP1A2
LEPONEX® FEVARIN®
(clozapine)
CYMBALTA® LUVOX®
HALDOL® TOFRANIL® MEBUTAN® ALEVE®
ZYPREXA® RILUTEK®
(cyclobenzaprine) (duloxetine)
(fluvoxamine) (haloperidol) (imipramine) (nabumetone)
(naproxen)
(olanzapine) (riluzole)
THEOLAIR® SIRDALUD® DYRENIUM® ZYFLO®
(theophylline) (tizanidine)
(triamterene) (zileuton) ZOMIG®
MINODIAB® DAONIL®
CELEBREX® LESCOL®
EPANUTIN® TOREM®
(zolmitriptan) (glipizide)
(glyburide) (fluvastatin) (torsemide)
DEPAKENE® MAREVAN® ACCOLATE®
(celecoxib) (phenytoin)
(valproic acid) (warfarin)
(zafirlukast) 9% 30% CYP3A4/A5/A7
Antihistamines: CHLORAMPHENICOL® (chlorpheniramine)
Benzodiazepines: XANAX®
HALCION®
(alprazolam) (triazolam)
Calcium Channel Blockers: NORVASC® TILDIEM® PLENDIL®
(amlodipine) (diltiazem) (felodipine)
ADALAT OROS® ISOPTIN®
(nifedipine) (verapamil)
HIV Antivirals: CRIXIVAN® NORVIR®
13% CYP2C9
Angiotensin II Blockers: COZAAR® APROVEL®
(losartan) (irbesartan)
NSAIDs: VOLTAREN® ADVIL® ALEVE®
FELDENE® (diclofenac)
(ibuprofen) (naproxen)
(piroxicam) 20%
FORTOVASE® VIRAMUNE®
(indinavir) (ritonavir)
(saquinavir) (nevirapine)
Macrolide antibiotics: KLACID® KETEK®
(clarithromycin) (telithromycin)
PDE-5 Inhibitors: VIAGRA® CIALIS®
(tadalafil) LEVITRA®
(sildenafil) (vardenafil)
ADVICOR® ZOCOR®
HMG CoA Reductase (atorvastatin) (simvastatin)
Inhibitors: LIPITOR®
(lovastatin)
Immune Modulators: RESTASIS®
(cyclosporine) 3% CYP2E1
Anesthetics: ETHRANE®
FLUOTHANE® FORANE®
PENTHRANE® SEVORANE®
(enflurane) (isoflurane)
Others: MUSCOL®
(halothane)
(methoxyflurane) (sevoflurane)
(chlorzoxazone)
CYP2D6
Antidepressants: TRYPTIZOL® ANAFRANIL® NORPRAMIN® CYMBALTA® PROZAC®
TOFRANIL® SEROXAT®
(amitriptyline) (clomipramine) (desipramine) (duloxetine)
(fluoxetine)
(imipramine) (paroxetine)
Determining CYP450 genotypes can help classify
patients into the right metabolizer status. Poor Metabolizers
In people who process a certain drug more slowly than normal because of a missing enzyme, the medication can build up in their system. This can increase the likelihood that it will cause side effects. These people may still be able to benefit from these medications, but at lower dosages.
Extensive Metabolizers
People with extensive metabolizers are more likely to benefit from treatment and have fewer side effects.
Intermediate Metabolizers
People with reduced enzyme function in processing drugs may not process some medications as well as normal metabolizers do. This can increase a risk of side effects and drug interactions.
Ultra-rapid Metabolizers
People in which medications leave the body too quickly, often before they have a chance to work properly. Physicians may elect to prescribe higher than usual doses of medication(s).
Antipsychotics: HALDOL®
RISPERDAL®
Beta Blockers: EUCARDIC®
RYTMONORM® TIMOPTOL®
(haloperidol) (risperidone)
(carvedilol) (timolol)
(propafenone)
Not all genotyping tests predict response or non-response to therapeutics. Refer to respective test package inserts as applicable.
Zanger UM, Klein K, Thomas M, Rieger JK, Tremmel R, Kandel BA, Klein M, Magdy T. Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. Clin Pharmacol Ther. 2014;95(3):258-61. Source: P450 Drug Interaction Table. Indiana University School of Medicine. Cited 2014 July.
http://medicine.iupui.edu/clinpharm/d- dis/clinical-table/
©2014 Luminex Corporation. All rights reserved. The trademarks mentioned herein are the property of Luminex or their respective owners.
AD1067.1014 For more information ✔ at
www.scientistlive.com/eurolab www.luminexcorp.eu
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120